SCOTUS backs generic firm Hikma in skinny label dispute

SCOTUS has delivered its ruling in a closely watched 'skinny label' lawsuit between Amarin and Hikma, which could have far-reaching implications.

'Skinny' generic Vascepa label case reaches US Supreme Court

SCOTUS has agreed to hear a patent dispute between Amarin and Hikma that could have implications for 'skinny labels' used by generic manufacturers.

Amarin hit hard as generics loom for fish oil drug Vascepa

Amarin gets FDA panel okay for new Vascepa indication

Amarin’s Vascepa gets priority review for cardiovascular lab...

Amarin’s cardio drug Vascepa (icosapent ethyl) has been granted Priority Review designation by the FDA after trial results showed it could reduce the risk of major cardio events by up to 25